Ixekizumab Eases Psoriatic Arthritis When TNF Inhibitor Fails

The selective interleukin-17A inhibitor ixekizumab improved signs and symptoms of active psoriatic arthritis (PsA) in patients who had failed prior biologic therapy in the phase 3 SPIRIT-P2 trial.
Reuters Health Information

http://ift.tt/2racI5H